Richard Byrd Biography and Net Worth

EVP and President, Interventional Segment of Becton, Dickinson and Company

Richard Byrd serves as executive vice president and president of the Interventional Segment. In this role, he is responsible for driving the global operational, commercial and financial performance of the three business units that comprise the Interventional Segment, including BD Peripheral Intervention, BD Surgery and BD Urology and Critical Care. He is also a member of the BD Executive Leadership Team.

Byrd most recently served as the worldwide president of BD Medication Delivery Solutions within the Medical segment. In that role, Byrd advanced BD’s leadership in Vascular Access Management, completing the integration of the Bard portfolio and driving a strong innovation pipeline. During the COVID-19 pandemic, he oversaw BD’s role in enabling global COVID-19 vaccination campaigns, including commitments of more than two billion injection devices worldwide. He also advanced BD’s “One-Stick Hospital Stay” vision to eliminate multiple needlesticks for in-patients and drive a new standard of care in vascular health.

Since joining BD in 2004, Byrd has demonstrated a proven track record of leveraging his strength in technology and innovation to drive growth while prioritizing customers’ needs, delivering operational efficiencies and developing talent across the globe. He previously held leadership roles within BD Life Sciences segment and Research and Development.

Byrd earned a master's degree in Mechanical Engineering from Stevens Institute of Technology and a Bachelor of Science degree in Mechanical Engineering from Virginia Tech.

What is Richard Byrd's net worth?: The estimated net worth of Richard Byrd is at least $1.68 million as of March 12th, 2025. Mr. Byrd owns 7,411 shares of Becton, Dickinson and Company stock worth more than $1,678,050 as of March 14th. This net worth evaluation does not reflect any other assets that Mr. Byrd may own. Learn More about Richard Byrd's net worth.
How do I contact Richard Byrd?: The corporate mailing address for Mr. Byrd and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at investor.relations@bd.com. Learn More on Richard Byrd's contact information.
Has Richard Byrd been buying or selling shares of Becton, Dickinson and Company?: During the past quarter, Richard Byrd has sold $436,325.40 in shares of Becton, Dickinson and Company stock. Most recently, Richard Byrd sold 1,940 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $224.91, for a transaction totalling $436,325.40. Following the completion of the sale, the executive vice president now directly owns 7,411 shares of the company's stock, valued at $1,666,808.01. Learn More on Richard Byrd's trading history.
Who are Becton, Dickinson and Company's active insiders?: Becton, Dickinson and Company's insider roster includes Richard Byrd (EVP and President, Interventional Segment ), Richard Byrd (EVP), Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), Jeffrey Henderson (Director), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Shana Neal (EVP and Chief People Officer), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), Bertram Scott (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.
Are insiders buying or selling shares of Becton, Dickinson and Company?: During the last year, Becton, Dickinson and Company insiders bought shares 1 times. They purchased a total of 1,500 shares worth more than $350,430.00. During the last year, insiders at the medical instruments supplier sold shares 13 times. They sold a total of 21,381 shares worth more than $4,907,213.31. The most recent insider tranaction occured on March, 12th when EVP Richard Byrd sold 1,940 shares worth more than $436,325.40. Insiders at Becton, Dickinson and Company own 0.4% of the company. Learn More about insider trades at Becton, Dickinson and Company.
Information on this page was last updated on 3/12/2025.

Richard Byrd Insider Trading History at Becton, Dickinson and Company

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/12/2025	Sell	1,940	$224.91	$436,325.40	7,411
11/28/2023	Sell	2,156	$238.47	$514,141.32	4,120
9/5/2023	Sell	459	$274.48	$125,986.32	3,444
2/3/2023	Sell	1,421	$248.60	$353,260.60	4,119

Richard Byrd Buying and Selling Activity at Becton, Dickinson and Company

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Today's Range

Now: $226.43

$221.98

$226.47

50 Day Range

MA: $232.78

$222.65

$249.75

2 Week Range

Now: $226.43

$218.75

$251.99

Volume

1,157,171 shs

Average Volume

1,519,508 shs

Market Capitalization

$65.02 billion

P/E Ratio

37.61

Dividend Yield

1.81%

Beta

0.35